273P Adjuvant immunotherapy in stage 3 acral melanoma - A retrospective experience in Singapore

March 1, 2026ESMO rare cancers.Open Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the efficacy of adjuvant anti-PD1 therapy in patients with stage 3 acral melanoma.
Retrospective cohort study of patients treated with anti-PD1 therapy.
Analysis of overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
Cox regression used to determine risk factors affecting survival outcomes.
Overall response rate of 23% with complete response in 5% and partial response in 18%.
Median PFS was 4.1 months with 24-month and 36-month PFS rates of 15.1% and 10.1%, respectively.
Median OS was 19.9 months with 24-month and 36-month OS rates of 39.2% and 33.6%.
Lack of response and metastatic disease significantly worsened PFS and OS, while female sex improved OS.

A retrospective analysis evaluates adjuvant immunotherapy outcomes in acral melanoma, indicating critical response factors.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Law et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share